TransCode Therapeutics Inc Stock

$0.42

8.20% today

Nasdaq, Apr 04, 09:18 pm CET

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

TransCode Therapeutics Inc Stock price

$0.46

-105,599.54 100.00% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

-0.07 12.54%

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$10.79m
Enterprise Value	$9.06m
P/E (TTM) P/E ratio	0.00
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.15
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-14.63m
Free Cash Flow (TTM) Free Cash Flow	$-15.87m
Cash position	$1.88m
EPS (TTM) EPS	$-265.83
P/S forward	35.97
EV/Sales forward	30.20
Short interest	48.80%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

TransCode Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast TransCode Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast TransCode Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from TransCode Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.55 0.55	34% 34% -
Gross Profit	-0.55 -0.55	34% 34% -
- Selling and Administrative Expenses	4.14 4.14	51% 51% -
- Research and Development Expense	9.38 9.38	19% 19% -
EBITDA	-14 -14	31% 31% -
- Depreciation and Amortization	0.55 0.55	34% 34% -
EBIT (Operating Income) EBIT	-15 -15	30% 30% -
Net Profit	-15 -15	24% 24% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

TransCode Therapeutics Inc Stock News

Neutral

PRNewsWire

●

8 days ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded enrollment No significant safety or dose limiting toxicities have been reported BOSTON , March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed...

Neutral

PRNewsWire

●

10 days ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

BOSTON , March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-mark...

Neutral

PRNewsWire

●

12 days ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BOSTON , March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase ...

More TransCode Therapeutics Inc News

Company Profile

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Head office	United States
CEO	Thomas Fitzgerald
Founded	2016
Website	www.transcodetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now